Claude Bernard University Lyon 1

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

Retrieved on: 
Lundi, janvier 30, 2023
Beauficel-en-Lyons, Novartis, Public health, Immunology, Claude Bernard University Lyon 1, Urinary tract infection, OXFORD, Hepatitis B, Merck Serono, Cancer, CSO, Novartis Institute for Tropical Diseases, Vaccine, Infection, Roche, Scripps Research, Secondary research, ISCB Senior Scientist Award, Drug discovery, Biomedical Research, Autoimmunity, Doctor of Philosophy, Inflammation, Medical device, Science, Genetics, Vaccitech

“We are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,” said Chief Executive Officer, Bill Enright.

Key Points: 
  • “We are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,” said Chief Executive Officer, Bill Enright.
  • “Dr.
  • “For the past six years, Tom has been integral in elevating Vaccitech’s profile and pipeline to serve a global patient community.
  • Dr. Pelletier brings extensive experience to Vaccitech in the areas of immunology, inflammation and infectious diseases.

Affluent Medical is evolving its governance to accelerate its development.

Retrieved on: 
Lundi, août 22, 2022
Paris, Degenerative disease, Veterinary medicine, Patient, ISIN, D, CEO, Technology, Hernia, Ticker, Executive Committee, DVM, Life expectancy, Doctor of Philosophy, Urinary incontinence, Death, R, Heart, Celebrity board director, Executive Committee of the Space Research Council, Board, Claude Bernard University Lyon 1, Senior, Union, Quality of life, Neurology, Innovation, Biomedical engineering, Polymer, Regulatory News Service, Observer, Board of directors, Company, Publication, General manager, Technology strategy, Scientific Committee on Emerging and Newly Identified Health Risks, Marketing, Trial of the century, Development, Research and development, Hemostasis, Pharmaceutical industry, Management, Medical device, Medical imaging, Research, Medtech, Director, Covidien, Medtronic

Affluent Medical is evolving its governance to accelerate its development.

Key Points: 
  • Affluent Medical is evolving its governance to accelerate its development.
  • I am particularly honored to be entrusted with the general management of Affluent Medical and I am excited about its product development.
  • Affluent Medical is developing very innovative products, addressing very important medical needs and markets.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Transgene’s Combined General Meeting of May 25, 2022

Retrieved on: 
Mercredi, mai 25, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Research, Claude Bernard University Lyon 1, European Society for Medical Oncology, University, SPH, Artificial intelligence, Risk, AstraZeneca, Oncology, Novartis, Medical Affairs Bureau, Immunotherapy, European Commission, Kite Pharma, List of life sciences, Therapy, Marketing, Institute, Vaccination, Century, EVP, Acquisition, Growth, Potyvirus, University of Milan, MDL, Doctor of Philosophy, AMF, Director general, National academy, Adult, TNG, Hematology, Corporate law, ESMO, Cell, European Organization for Quality, Transgene, Ernst & Young, Board, Law, Patient, Treatment, Ernst, NEC, National Cancer Institute, Forward-looking statement, European Commission–AstraZeneca COVID-19 vaccine dispute, Precision medicine, Gilead Sciences, CEO, Pharmaceutical industry, Vaccine, Cancer, Axicabtagene ciloleucel, Euronext, EU

Detailed voting results are available on Transgenes website, under the heading Investors > General Meeting.

Key Points: 
  • Detailed voting results are available on Transgenes website, under the heading Investors > General Meeting.
  • Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.
  • Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Lon Brard Center in Lyon since 2014.
  • With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual.

Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.

Retrieved on: 
Mercredi, janvier 19, 2022
Urinary incontinence, Biomedical engineering, Patient, Kalio, Cardiology, Medtronic, Board of directors, International business, MBA, Knowledge, ISIN, Biomedicine, CEO, Emlyon Business School, Claude Bernard University Lyon 1, Industry, Marketing, Urology, Company, Hitachi, Boston Scientific, Regulatory News Service, EV3, Pathology, Biosensor, Board, Medical imaging, Management

Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.

Key Points: 
  • Affluent Medical : Appointment of a new independent board member to the Affluent Medical Board of Directors.
  • Affluent Medical (ISIN code: FR0013333077 - mnemonic: AFME), a French medtech specialised in the international development and industrialisation of innovative medical prostheses - at a clinical stage - to treat urinary incontinence and the pathology of the heart mitral valve, today announced the appointment of Soad El Ghazouani as a new independent board member to the Affluent Medical Board of Directors.
  • Soad El Ghazouani, the new member of Affluent Medical's Board of Directors, said, "Affluent Medical's two devices, Epygon and Kalios, have the potential to address broad unmet medical needs in the field of interventional cardiology.
  • Affluent Medical's Board of Directors is now composed of the following directors:

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

Retrieved on: 
Jeudi, décembre 9, 2021
Acceleration, Company, COO, Intellia Therapeutics, University of California, San Francisco, Ophthalmology, Leadership, CSO, Drug development, Spark Therapeutics, Patient, Therapy, Pharming, City, Board, Doctor of Philosophy, Cellectis, Program, University, Claude Bernard University Lyon 1, City of Hope, Retina, AAV, CRISPR, Nasdaq, Management, Pharmaceutical industry

Paris, December 9, 2021 SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Dr Mehdi Gasmi, PhD, as Chief Operating Officer (COO), as well as other senior appointments, further strengthening the SparingVision team.

Key Points: 
  • Paris, December 9, 2021 SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Dr Mehdi Gasmi, PhD, as Chief Operating Officer (COO), as well as other senior appointments, further strengthening the SparingVision team.
  • Mehdi Gasmi is a seasoned executive with over 25 years of experience across the gene therapy drug development field, including in ophthalmology indications.
  • Dr Mehdi Gasmi, PhD, commented: SparingVisions disruptive approach to combat retinal disease is inspiring and I am excited to be joining such a visionary team.
  • SparingVision is also delighted to announce the appointments of Dr Raffaella Toso, PhD, as VP Corporate Development and Florence Paliargues, Pharm.

ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

Retrieved on: 
Mercredi, novembre 10, 2021
150, GMP, Safety, Organic acid, University, Cancer, CAC All-Tradable, ALL, University of Paris, Asparagine, Asparaginase, Medicine, CEO, Acute lymphoblastic leukemia, Technology, Nasdaq, Food, Rheology, Growth, Paper, RBC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Drug, ISIN, Company, Claude Bernard University Lyon 1, Half-life, Metabolism, Therapy, Red blood cell, CAC, CAC Mid 60, IST, Survival, Pancreatic cancer, Patient, University of Colorado, Pharmaceutical industry, Medical device

In conclusion, a full and in-depth characterization of the physiological, biophysical, metabolomic, proteomic and cellular properties of RBCs after drug loading was performed.

Key Points: 
  • In conclusion, a full and in-depth characterization of the physiological, biophysical, metabolomic, proteomic and cellular properties of RBCs after drug loading was performed.
  • ERYTECH is committed to advancing the field of RBC-based therapeutics in difficult to treat cancers and selected rare diseases.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.